News & Updates

A negative association exists between adalimumab (ADA) concentrations and markers of inflammatory disease activity in rheumatoid arthritis (RA), including interleukin 6 (IL-6), reveals a study. Notably, ADA concentrations from 5 to 7 mg/L over the dose interval seem to contribute to better disease control.

Increased levels of serum C-reactive protein (CRP) may contribute to shorter survival in patients with idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (fHP), rheumatoid arthritis (RA)-associated interstitial lung disease (ILD), or systemic sclerosis (SSc)-associated ILD at 5 years.

The use of abatacept in adults at high risk of rheumatoid arthritis helps protect against disease onset, as shown in the phase IIB APIPPRA study.

A recent study has reported the prevalence of serious infection (SI) among patients with systemic lupus erythematosus (SLE) following treatment with rituximab (RTX).

Use of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as an instrument in psoriatic arthritis (PsA) demonstrates “reasonable” responsiveness but falls short of distinguishing peripheral PsA from axial (ax)PsA, according to a recent study.